Atezolizumab, a PD-L1 inhibitor, received FDA approval in 2020 to be used with cobimetinib (MEK inhibitor) and vemurafenib (BRAF inhibitor) in patients diagnosed with BRAF V600 unresectable or metastatic melanoma. The gene discussed is CD274; the disease is metastatic melanoma.